New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
07:07 EDTATRSAntares Pharma announces presentation of poster on VIBEX injector
Antares Pharma announced the presentation of a scientific poster at the 16th International Congress of Endocrinology and the Endocrine Society’s 96th Annual Meeting & Expo held in Chicago, Illinois. The poster presents the final pharmacokinetic and safety results from 29 randomized patients treated with a once-weekly injection of testosterone administered subcutaneously with the company’s VIBEX QuickShot auto injector. The company’s previously reported interim results from this multi-center phase 2 clinical study were also presented as a scientific abstract at the same meeting. Results from 29 adult males ages 31 to 69 with hypogonadism symptoms and screening testosterone blood levels less than 300 ng/dl were reported. These patients were randomized into two groups and followed for 10 weeks. The first group received weekly 50 mg testosterone administered subcutaneously with a novel auto injector, and the second group received 100 mg of testosterone using the same device and time sequence. The mean testosterone baseline was 244 ng/dL in the 50 mg group and 243.7ng/dL in the 100 mg group. Testosterone levels normalized within hours of the first dose. At week six of the study when patients were at steady state pharmacokinetic conditions, the 50 mg and 100 mg groups had average plasma testosterone values within the normal range at 422ng/dL and 896 ng/dL, respectively. Rapid restoration, consistent maintenance of normal testosterone levels and dose proportionality of the 50 mg and 100 mg strengths were thereby demonstrated. The once-weekly, virtually pain-free administration took three to four seconds and consistently provided a precise dose of 0.5 ml.
News For ATRS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2015
16:21 EDTATRSAntares Pharma gets written notice of termination of agreement from Pfizer
On December 12, 2011, Antares Pharma (ATRS) entered into a licensing agreement with Pfizer (PFE) Consumer Healthcare for one of our drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. On October 5, the Company received a written notice of termination of the Agreement from Pfizer. Pfizer informed the Company that the product Pfizer was developing failed to meet pre-specified endpoints in a clinical study. Accordingly, the Agreement will terminate on November 5.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use